Regulation of the Src protein tyrosine kinase  by Superti-Furga, Giulio
FEBS Letters 369 (1995) 62-66 FEBS 15708 
Minireview 
Regulation of the Src protein tyrosine kinase 
Giulio Superti-Furga* 
Differentiation Programme, European Molecular Biology Laboratory, Meyerhofstrasse 1, 69012 Heidelberg, German), 
Received 24 May 1995 
Abstract Members of the Src family of protein tyrosine kinases 
are involved in a variety of cellular processes, including cell 
growth, cell differentiation and neuronal signalling. N-terminal 
to the catalytic domain, Src family members contain a Src homol- 
ogy 2 (SH2) domain, a Src homology 3 (SH3) domain, and a 
unique domain, all capable of protein-protein interactions. Nega- 
tive regulation by phosphorylation of a conserved tyrosine residue 
at the C-terminal tail of the molecules is characteristic of this 
family of enzymes. Phosphorylation of this residue causes the 
intramolecular interactions of the SH2 domain with the tail, and 
of the SH3 domain with an as yet undefined region, probably 
within the catalytic domain. Enzymatically active Src family ki- 
nases, on the other hand, are phosphorylated at a tyrosine in the 
middle of the catalytic domain and phosphorylation of this residue 
is a prerequisite for high activity. Regulators of these enzymes 
may thus act by altering the phosphorylation state of the two key 
tyrosine residues or by interfering with the regulatory intramol- 
ecular interactions, either by direct binding or by modification of 
the interfaces involved. 
Key words'." Src protein tyrosine kinase; SH3 domain; 
SH2 domain; Regulation of enzyme activity; 
Autophosphorylation site 
1. Structure 
There are at least nine members of Src family kinase in 
mammals and birds: Src, Fyn, Yes, Lyn, Hck, Fgr, Lck, Blk 
and Yrk. Sequence identities among the different family mem- 
bers exceed 70%. Expression of Src, Fyn and Yes is ubiquitous, 
while other members of the family have a more restricted ex- 
pression pattern, several being expressed only in cells of the 
hematopoietic system (reviewed in [1,2]). Within the first 15 
N-terminal residues, all Src family members bear a signal for 
myristylation and most also one for palmitoylation (reviewed 
in [3], Fig. 1), which direct he association of these proteins with 
cellular membranes. The following 40-70 amino acids are 
poorly conserved among the different members. This region, 
termed the unique domain, has in some cases been shown to 
participate in the interaction with other proteins (reviewed in 
[4]). C-terminal to the unique domain is the SH3 domain, a 
structure of about 60 residues capable of protein-protein ter- 
action with regions of proteins which form left-handed pol- 
yproline type II helices (reviewed in [5 7]). The three-dimen- 
sional structure of several SH3 domains of Src family members 
is known, and the molecular details of their interaction with 
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peptides have been elucidated [8,9]. Several proteins able to 
interact with the SH3 domain of Src family members have been 
identified (reviewed in [7,10]). Next to the SH3 domain is the 
SH2 domain, comprising about 100 residues. The SH2 domain 
is a high-affinity binding unit for phosphotyrosine-containing 
proteins (reviewed in [5,7]), and is frequently found in proteins 
involved in signal transduction [11]. The SH2 domains of Src 
family members mediate interactions with receptor-type pro- 
tein tyrosine kinases and with proteins present in focal adhe- 
sions, and may also mediate the interaction with protein sub- 
strates of Src kinases [11,12]. The structure of the SH2 domain 
of several Src family members has been solved [13-17] and 
provides amolecular basis to the understanding of the observed 
binding specificity [18,19]. C-terminal to the SH2 domain is the 
catalytic domain, which is very similar to, though bearing some 
distinct features from, those of other protein tyrosine kinases, 
and is reviewed elsewhere [20,21]. No structure of a protein 
kinase of the Src family is yet available. The catalytic domain 
is followed by a short 'tail' containing a conserved tyrosine 
residue, a site of regulatory phosphorylation characteristic of 
the Src family of proteins (see below). 
2. Function 
In recent years we have seen a rapid improvement in our 
understanding of the function of Src family members. Proteins 
of this family have been found associated with several cell 
surface receptors, some with tyrosine kinase activity, others 
with no obvious catalytic function (reviewed in [4,22,23]). In 
many cases, activation of these receptors causes an increase in 
the activity of Src family members. A direct functional involve- 
ment of Src family members in intracellular signalling through 
these receptors has been demonstrated in several cases (re- 
viewed in [22,23]). A genetic approach to the function of Src 
family kinases has become possible through homologous re- 
combination at the loci of genes coding for Src family members 
in mice (reviewed in [24]). Surprisingly, mice defective for any 
single Src family gene show relatively minor phenotypes or no 
detectable phenotype at all, suggesting partial functional com- 
pensation among Src family members. Nevertheless, the mu- 
tant mice clearly demonstrated the involvement of given Src 
family members in specific functions. Fyn - / -  mice, for exam- 
ple, show defective T-cell receptor signalling in thymocytes, 
abnormal development of the hippocampus and impairment of 
long-term potentiation [25 27]. Recent reports show that the 
phenotype of double and triple mutants is more than additive, 
suggesting that in some cases, Src family members indeed over- 
lap functionally [28,29]. 
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Fig. 1. Topology of the Src family of protein tyrosine kinases. Approximate numbers of amino acids comprising the various domains in Src family 
members are indicated. The sites of myristoylation (Gly2) and palmitoylation (cysteine residues within the first 10 residues) are shown, as well as two 
major egulatory phosphorylation sites. See text for details. Abbreviations: unique, unique domain; SH3, Src homology 3 domain; SH2, Src homology 
2 domain; aa, amino acid; N, N-terminus; C, C-terminus. 
3. Regulation 
All Src family members are negatively regulated by phospho- 
rylation of a conserved tyrosine in the tail at the C-terminus of 
the molecules (reviewed in [30,31], see also [32]). Src itself has 
been the most widely studied, and will therefore be discussed 
here as a paradigm for all Src family kinases. Mutation of 
Tyr527, the regulatory tyrosine in the tail of chicken c-Src, to 
phenylalanine is sufficient to convert he proto-oncogene to an 
oncogene, and dephosphorylation r mutation of this residue 
is accompanied by an at least 10-fold increase in kinase activity 
[33]. Members of a related but distinct class of protein tyrosine 
kinases, the Csk family, currently consisting of two members, 
Csk itself and Ctk/Ntk/Matk/Hyl/Lsk, are responsible for this 
phosphorylation (reviewed in [21]). Inactivation of the Csk gene 
by homologous recombination i the mouse has shown that 
Csk is largely responsible for phosphorylation of Src in the 
embryo (reviewed in [24,31]). Phosphatases specifically acting 
on Tyr527, on the other hand, have not been identified yet. 
Hanafusa nd colleagues originally proposed a model accord- 
ing to which the negative ffect of phosphorylation f Tyr527 
was mediated by an intramolecular interaction between the 
phosphorylated tail and the SH2 domain of the same molecule 
[34]. Indeed, mutations in the Src SH2 can activate the kinase, 
and in some cases cause Src to transform fibroblasts [35-37]. 
Much experimental evidence for this interaction has been pro- 
vided over the years [3842]. 
From mutational analysis there is also evidence for a nega- 
tive role of the SH3 domain in Src regulation. Some mutations 
derived from the v-Src SH3 domain, when transplanted into 
c-Src, are sufficient to partially activate the enzyme [43,44] and 
a deletion of the SH3 domain rendered c-Src able to transform 
chicken embryo fibroblasts [37]. It was later found by several 
groups that the activity of Src alleles mutated in their SH3 
domain, unlike the activity of wild-type Src, was not affected 
by C-terminal phosphorylation when coexpressed along with 
Csk in yeast [42,45,46]. Peptide binding experiments revealed 
that the SH3 domain was necessary in order for the 
phosphorylated tail to interact stably with the SH2 domain [42]. 
A so-called snail model for the regulated state of Src was de- 
rived, according to which the phosphorylated tail interacts with 
the SH2 domain while the nearby SH3 domain interacts with 
some other part of the molecule [42]. In Src, proline-rich mo- 
tives and therefore potential SH3 domain interaction sites, are 
found in the unique domain and at the end of the catalytic 
domain. We have mutated both regions and found that neither 
is involved in regulation by C-terminal phosphorylation 
(G.S.F., unpublished results). On the other hand we have re- 
cently shown that the same conserved residues involved in the 
interaction of the SH3 domain with other proteins participate 
in intramolecular regulation, implying that the function of the 
SH3 domain in Src regulation requires the same ligand-binding 
surface [47]. The crystal structure of the SH3 and SH2 domains 
of Lck published by Eck et al. rules out the possibility that the 
ligand binding surface of the SH3 interacts with the SH2 do- 
main in cis, but rather points to a possible interaction between 
the SH2 domain and the SH3 domain of two Src molecules in 
trans [17]. We have purified Src to homogeneity in its repressed 
state, phosphorylated at Tyr527, and found that it runs as a 
monomer on sizing columns, arguing against he existence of 
regulated imers (A. Weijland, G.S.F., S.A. Courtneidge and 
R. Wierenga, unpublished results). With what portion of the 
molecule then does the SH3 domain interact ? If we exclude the 
unique and the SH2 domains, we must conclude that the SH3 
domain interaction site is in an exposed region of the catalytic 
domain. While there is no obviuos proline-rich region to candi- 
date, on the surface of globular proteins, left-handed polypro- 
line type II helices might form even in the absence of any 
proline residue [48], making it possible to the Src SH3 to bind. 
Moreover, the affinity of the SH3 with the putative interaction 
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Fig. 2. Models of active and inactive forms of Src. The figure shows cartoons of our current models of Src regulation. The unique domain is not 
shown. The catalytic domain is drawn as a bilobal structure consisting of the smaller ATP-binding lobe and of the larger substrate-binding lobe. 
The SH2 domain is shown as a hemisphere with a cavity to accommodate a phosphotyrosine residue. The SH3 domain is also drawn as a hemisphere 
with a zig-zag ligand-binding surface. The C-terminal tail is drawn in white. The activation loop is drawn as a short black line in the cleft between 
the small ATP-binding lobe and the large substrate-binding lobe of the kinase domain. The letter 'P' indicates a phosphorylated tyrosine. The letter 
'Y' stands for tyrosine. The two white boxes represent a protein containing a poly-proline type II helix, able to bind with high affinity to the Src 
SH3 domain, and a protein phosphorylated on tyrosine, able to bind with high affinity to the Src SH2 domain. (A D) Inactive forms of Src. (E,F) 
Active forms of Src. (A) Regulated Src. Phosphorylated Tyr527 interacts with the SH2 domain, the SH3 domain interacts with an as yet unidentified 
region in the catalytic domain, possibly within the small lobe. This is the so-called closed conformation. Tyr416 is not phosphorylated. The activity 
is low. (B) Proteins able to interact with high affinity with the SH3 and/or the SH2 domains keep Src in the 'open' conformation, despite 
phosphorylation atTyr527. The kinase activity, however, is low because Tyr416 is unphosphorylated, possibly due to the action of a phosphatase. 
The 'opening' effect may also be induced by phosphorylation of the interaction surfaces of the SH3 and SH2 domains. (C) Tyr527 is not 
phosphorylated and therefore Src is in the 'open' conformation. Absence of Tyr416 phosphorylation keeps the kinase inactive. (D) Despite 
phosphorylation atTyr416, Src is inactive because phosphorylation atTyr527 causes Src to adopt the 'closed' conformation. This conformation is 
dominant over the state of the activation loop. (E) Active Src. Association of the SH3 and/or the SH2 domains of Src with proteins binding with 
high affinity prevents the intramolecular interactions of these domains. The kinase activity is derepressed. Tyr416 is phosphorylated. As in B, the 
'opening' effect may also be induced by phosphorylation f the interaction surfaces of the SH3 and SH2 domains. (F) In the absence of phosphoryl- 
ation of Tyr527 in the tail, there is no intramolecular ssociation with the SH2 domain. The kinase is derepressed. Tyr416 is phosphorylated. See 
text for details. 
site should be rather weak, the interaction being already kinet- 
ically favored by its intramolecular nature and because of the 
necessity of  being easily reversed. Accordingly, the affinity of 
the Src SH2 domain for a peptide modelled on the tail of Src 
is quite weak [19,40,49]. Further mutagenesis studies and the 
solution of the structure of Src in the 'closed' conformation will 
allow identification of the SH3 interaction site. 
Activated forms of Src, like v-Src or Src expressed in yeast 
in the absence of Csk, are phosphorylated at Tyr416 in the 
so-called activation loop, a region essential for the activity of 
several serine/threonine and tyrosine kinases and a site of reg- 
ulatory phosphorylation (reviewed in [50,21], see also [51,52]). 
While Tyr416 is clearly a site of  autophosphorylation in trans, 
it may also be phosphorylated by kinases other than Src. Pinna 
and co-workers have purified an activity from spleen, distinct 
from any known Src family member, able to specifically phos- 
phorylate the 'autophosphorylation' site of Src family kinases 
[53]. When introduced in cells lacking Csk, where Src family 
kinases are activated, or even in cells lacking both endogenous 
Src and Csk, a catalytically defective form of Src is 
phosphorylated at Tyr416 ([54] and A. Imamoto and P. Sori- 
ano, personal communication), suggesting that Src family 
members might activate ach other, or be activated by yet other 
kinases. Mutation of Tyr416 to phenylalanine seriously impairs 
the ability of activated c-Src to transform cells, but has only 
very little effect on the transformation potential of v-Src 
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(reviewed in [21,30]). In vitro, the difference in the specific 
kinase activity between wild-type Src and Src Y416F is less than 
five-fold. While this discrepancy is still unexplained at the 
moment, Y416F Src is at least 30-fold less active than wild-type 
Src when expressed in yeast (M. Koegl, S.A. Courtneidge and 
G.S.F., manuscript submitted), suggesting that the role of 
Tyr416 is currently underestimated. Moreover it is clear from 
a number of studies, including mass spectrographic analysis, 
that phosphorylations at Tyr416 and at Tyr527 are not mutu- 
ally exclusive ([55], A. Weijland, G.S.F., S.A. Courtneidge and 
R. Wierenga, unpublished results). 
4. Modulation 
The data on Src regulation discussed so far suggest that there 
are several ways in which the activity of Src can be modulated. 
Phosphorylation of Tyr527 causes a rearrangement of the mol- 
ecule associated with a severe reduction in enzyme activity 
('closed' conformation, Fig. 2A). In this conformation, both the 
SH2 domain and the SH3 domain are engaged intramolecularly 
and are therefore not accessible for interaction with other pro- 
teins. Dephosphorylation f Tyr527 is certainly sufficient o 
destabilize this conformation and de-repress the enzyme ('open' 
conformation, Fig. 2F). However, if Src is not phosphorylated 
at Tyr416, the enzymatic activity is low (Fig. 2C). Interactions 
of heterologous proteins with high affinity for the Src SH2 
domain will also result in destabilisation f the repressed state, 
activating the enzyme ([40], Fig. 2E). Such an event might occur 
at recruitment of Src to activated tyrosine kinase receptors and 
has been mimicked with phosphorylated peptides modelled on 
the PDGF receptor and the CSF-1 receptor Src binding sites 
[49]. Recent results have shown that SH2-domain-containing 
tyrosine kinases display a substrate specificity that matches the 
binding preferences of their SH2 domain [12], suggesting that 
once a substrate is phosphorylated by Src, it might cause the 
activation of more Src molecules in a positive feedback loop. 
Activation of Src by proteins binding to its SH3 domain, on 
the other hand, has not yet been demonstrated (Fig. 2E). Such 
a mechanism ight, however, operate during the localization 
of Src to focal adhesions [56], sites where Src is presumed to 
be active and phosphorylate, among other proteins, focal adhe- 
sion kinase (FAK). If, at focal adhesions, Src requires constant 
anchoring through the SH3 domain, freezing the enzyme in the 
'open' conformation, a possible requirement for down-regula- 
tion of Src activity might be fulfilled by phosphatases acting on 
Tyr416 (Fig. 2 B). Our model predicts that modification of the 
ligand-binding surfaces of either the SH2 or the SH3 domains 
would result in destabilization f the closed form. Such a mod- 
ification has recently been described by Broome and Hunter, 
who found that after PDGF stimulation, mouse Src became 
phosphorylated at Tyr138 in the SH3 domain, resulting in an 
impairment of the binding potential of the SH3 domain (M. 
Broome and T. Hunter, personal communication). Mutation of 
Tyr136, the corresponding residue in chicken Src, to alanine, 
abolishes regulation of Src by C-terminal phosphorylation [47], 
raising the possibility that phosphorylation f Tyr136 (Tyr138) 
would indeed activate Src. 
In summary there seem to be several ways in which Src may 
adopt the 'open' conformation and possibly also several ways 
in which further egulatory constraints can be superimposed on
the open conformation. While we might have identified some 
of the basic regulatory mechanisms, their role within the cell 
remains to be elucidated. 
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